Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study - PubMed
6 hours ago
- #Hyperglycemia
- #Teprotumumab
- #Thyroid Eye Disease
- Teprotumumab, an FDA-approved treatment for thyroid eye disease (TED), is associated with an increased risk of hyperglycemia.
- A large multinational cohort study compared 792 teprotumumab-treated patients with 792 matched controls using TriNetX data.
- At 5 years, teprotumumab significantly increased risks: prediabetes (HR 2.03, 24% vs. 10%), diabetes (HR 2.23), and need for antidiabetes medications (HR 1.68).
- The absolute risk increase was modest, supporting routine glucose monitoring and individualized risk-benefit assessment for TED patients.